Your browser doesn't support javascript.
loading
Episignature analysis of moderate effects and mosaics.
Oexle, Konrad; Zech, Michael; Stühn, Lara G; Siegert, Sandy; Brunet, Theresa; Schmidt, Wolfgang M; Wagner, Matias; Schmidt, Axel; Engels, Hartmut; Tilch, Erik; Monestier, Olivier; Destree, Anne; Hanker, Britta; Boesch, Sylvia; Jech, Robert; Berutti, Riccardo; Kaiser, Frank; Haslinger, Bernhard; Haack, Tobias B; Garavaglia, Barbara; Krawitz, Peter; Winkelmann, Juliane; Mirza-Schreiber, Nazanin.
Afiliação
  • Oexle K; Neurogenetic Systems Analysis Group, Institute of Neurogenomics, Helmholtz Munich, 85764, Neuherberg, Germany. konrad.oexle@helmholtz-muenchen.de.
  • Zech M; Institute of Neurogenomics,Helmholtz Munich, 85764, Neuherberg, Germany. konrad.oexle@helmholtz-muenchen.de.
  • Stühn LG; Institute of Human Genetics, Technical University of Munich, School of Medicine, 81675, Munich, Germany. konrad.oexle@helmholtz-muenchen.de.
  • Siegert S; Institute of Neurogenomics,Helmholtz Munich, 85764, Neuherberg, Germany.
  • Brunet T; Institute of Human Genetics, Technical University of Munich, School of Medicine, 81675, Munich, Germany.
  • Schmidt WM; Institute of Medical Genetics and Applied Genomics, University of Tuebingen, 72076, Tübingen, Germany.
  • Wagner M; Centre for Rare Diseases, University of Tuebingen, 72076, Tuebingen, Germany.
  • Schmidt A; Department of Pediatric and Adolescent Medicine, Medical University of Vienna, 1090, Wien, Austria.
  • Engels H; Institute of Human Genetics, Technical University of Munich, School of Medicine, 81675, Munich, Germany.
  • Tilch E; Neuromuscular Research Department, Center for Anatomy and Cell Biology, Medical University of Vienna, 1090, Vienna, Austria.
  • Monestier O; Institute of Human Genetics, Technical University of Munich, School of Medicine, 81675, Munich, Germany.
  • Destree A; Institute of Human Genetics, School of Medicine, University Hospital Bonn, 53127, Bonn, Germany.
  • Hanker B; Institute of Human Genetics, School of Medicine, University Hospital Bonn, 53127, Bonn, Germany.
  • Boesch S; Neurogenetic Systems Analysis Group, Institute of Neurogenomics, Helmholtz Munich, 85764, Neuherberg, Germany.
  • Jech R; Institute of Neurogenomics,Helmholtz Munich, 85764, Neuherberg, Germany.
  • Berutti R; Centre de Génétique Humaine, Institut de Pathologie et de Génétique ASBL, 6041, Gosselies, Belgium.
  • Kaiser F; Centre de Génétique Humaine, Institut de Pathologie et de Génétique ASBL, 6041, Gosselies, Belgium.
  • Haslinger B; Institute of Human Genetics, Universitätsklinikum Schleswig-Holstein, 23538, Lübeck, Germany.
  • Haack TB; Department of Neurology, Medizinische Universität, 6020, Insbruck, Austria.
  • Garavaglia B; Department of Neurology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, 12108, Prague, Czech Republic.
  • Krawitz P; Institute of Neurogenomics,Helmholtz Munich, 85764, Neuherberg, Germany.
  • Winkelmann J; Institute of Human Genetics, Technical University of Munich, School of Medicine, 81675, Munich, Germany.
  • Mirza-Schreiber N; Institute of Human Genetics, Universitätsklinikum Essen, 45122, Essen, Germany.
Eur J Hum Genet ; 31(9): 1032-1039, 2023 09.
Article em En | MEDLINE | ID: mdl-37365401
ABSTRACT
DNA methylation classifiers ("episignatures") help to determine the pathogenicity of variants of uncertain significance (VUS). However, their sensitivity is limited due to their training on unambiguous cases with strong-effect variants so that the classification of variants with reduced effect size or in mosaic state may fail. Moreover, episignature evaluation of mosaics as a function of their degree of mosaicism has not been developed so far. We improved episignatures with respect to three categories. Applying (i) minimum-redundancy-maximum-relevance feature selection we reduced their length by up to one order of magnitude without loss of accuracy. Performing (ii) repeated re-training of a support vector machine classifier by step-wise inclusion of cases in the training set that reached probability scores larger than 0.5, we increased the sensitivity of the episignature-classifiers by 30%. In the newly diagnosed patients we confirmed the association between DNA methylation aberration and age at onset of KMT2B-deficient dystonia. Moreover, we found evidence for allelic series, including KMT2B-variants with moderate effects and comparatively mild phenotypes such as late-onset focal dystonia. Retrained classifiers also can detect mosaics that previously remained below the 0.5-threshold, as we showed for KMT2D-associated Kabuki syndrome. Conversely, episignature-classifiers are able to revoke erroneous exome calls of mosaicism, as we demonstrated by (iii) comparing presumed mosaic cases with a distribution of artificial in silico-mosaics that represented all the possible variation in degree of mosaicism, variant read sampling and methylation analysis.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anormalidades Múltiplas / Metilação de DNA Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anormalidades Múltiplas / Metilação de DNA Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article